Groundbreaking advancements in medical research have led to the development of bispecific antibody therapy. This new treatment is designed to target and destroy cancer cells with the help of the patient’s immune system. At NJ Cancer Care, we’re proud to offer cutting-edge treatments like bispecific antibody therapy. It provides new hope for patients whose cancer may not respond to standard therapies, giving them access to more personalized and precise care options.
“Bispecific antibody therapy represents a monumental shift in personalized oncology. By directly bridging a patient’s immune cells to cancer cells, we can target hard-to-treat malignancies with unprecedented accuracy.”
— Medical Oncology Team, NJ Cancer Care
What Are Bispecific Antibodies?
Bispecific antibodies work by directing the patient’s T cells to the cancer cells, helping the immune system work more effectively. The antibodies are delivered into the body through an infusion or an injection. Once in the body, the antibody binds to two targets—one side attaches to the cancer cell, and the other connects with the T cell—bringing them together to trigger a more focused immune response.
Who Is Eligible for Bispecific Antibody Therapy?
Bispecific antibody therapy is available to patients diagnosed with the following cancers:
- Acute Lymphoblastic Leukemia
- Uveal Melanoma
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Multiple Myeloma
- Extensive-Stage Small Cell Lung Cancer
How Is Bispecific Antibody Therapy Administered?
Bispecific antibodies are administered in either a hospital setting or an outpatient infusion center.
Healthcare providers use step-up dosing to administer treatment. This gradually increases the amount of medication given during each treatment to minimize side effects. After the initial step-up dosing is completed, bispecific therapy may continue at regular scheduled dosing intervals or as maintenance therapy.
What Are the Benefits of Bispecific Antibody Therapy?
Because bispecific antibodies directly bind immune cells to cancer cells, this treatment is often able to deliver a more accurate immune response in patients with cancer that has been resistant to other treatment options. Studies indicate that bispecific antibodies have shown improvements in outcomes for multiple malignancies.
NJ Cancer Care Is Your Trusted Resource for Leading-Edge Cancer Treatment
NJ Cancer Care is proud to provide the latest therapies based on the most recent advancements in cancer research. Our team of experts provides comprehensive support from consultation through treatment and can help determine if bispecific therapy is right for you. Understanding all available options can empower you to make informed decisions about your care.
Frequently Asked Questions (FAQs)
How does bispecific antibody therapy differ from standard chemotherapy?
Unlike traditional chemotherapy, which targets rapidly dividing cells throughout the body, bispecific antibody therapy is a form of targeted immunotherapy. It specifically connects your immune system’s T cells directly to cancer cells to destroy them.
Are there side effects associated with bispecific antibody therapy?
Because this therapy activates the immune system, potential side effects can include Cytokine Release Syndrome (CRS) or immune-related reactions. Step-up dosing is used specifically to mitigate and minimize these side effects.
How do I know if I am a candidate for this treatment?
Eligibility depends on your specific cancer type, stage, and previous treatment history. Schedule a consultation with an oncologist at NJ Cancer Care to evaluate whether bispecific antibody therapy is suitable for your treatment plan.
Contact NJ Cancer Care at (973) 751-8880 to learn more about bispecific antibody therapy or to schedule a consultation with an oncology specialist at our Belleville, Montclair offices.